Concepedia

Lindsay Peltz

LP

Statistics

Publications

3

Citations

242

H-Index

3

Active since

2012

Affiliations

Agilent Technologies (United States)(Current)

Lindsay Peltz is an author at Agilent Technologies (United States) specializing in medicine, pembrolizumab therapy, and oncology.

Publications per year

2012–2021

3

Publications

3

Resveratrol Exerts Dosage and Duration Dependent Effect on Human Mesenchymal Stem Cell Development

Lindsay Peltz, Jessica Gómez, Maribel Marquez et al. · PLoS ONE · 2012 · 124 citations · Full text

, , +12

Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.

Karina Kulangara, Debra Hanks, Stephanie Waldroup et al. · Journal of Clinical Oncology · 2017 · 90 citations

, , +17

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx

Megan Kalpakoff, Stephanie Hund, Jeanette Musser et al. · Applied immunohistochemistry & molecular morphology · 2021 · 28 citations · Full text

, , +14

1–3 of 3